Skip to main navigation
Skip to search
Skip to main content
Aston Research Explorer Home
Help & FAQ
Home
Research units
Profiles
Research Outputs
Datasets
Student theses
Activities
Press/Media
Prizes
Equipment
Search by expertise, name or affiliation
Anti-obesity fixed-dose combinations
Clifford J. Bailey
, Caroline Day
School of Biosciences
Aston Research Centre for Health in Ageing
College of Health and Life Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Anti-obesity fixed-dose combinations'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Side Effect
100%
Diabetes Mellitus
100%
Monotherapy
100%
Maturity Onset Diabetes of the Young
100%
Glycon
100%
Hyperglycemia
100%
Low Drug Dose
100%
Blood Glucose
100%
Drug Megadose
100%
Dyslipidemia
100%
Patient Compliance
100%
Drug Dose Titration
100%
Single Drug Dose
100%
Diseases
100%
Adverse Effect
100%
Keyphrases
Anti-obesity
100%
Two-agent
100%
Glucose-lowering Drugs
100%
Mode of Action
100%
Fixed-dose Combination
100%
Pill Burden
100%
Multiple Medications
100%
Hyperglycemia
50%
Adverse Effects
50%
Type 2 Diabetes Mellitus (T2DM)
50%
Metformin
50%
Monotherapy
50%
High Dose
50%
Single Tablet
50%
Daily Dose
50%
Blood Glucose Reduction
50%
Dyslipidemia
50%
Patient Adherence
50%
One-at-a-time
50%
Hypertension Management
50%
Dose Titration
50%
Ant Diabetic
50%
Nursing and Health Professions
Pill
100%
Side Effect
50%
Diabetes Mellitus
50%
Glucose Blood Level
50%
Monotherapy
50%
Non Insulin Dependent Diabetes Mellitus
50%
Hyperglycemia
50%
Metformin
50%
Low Drug Dose
50%
Patient Compliance
50%
Single Drug Dose
50%
Drug Megadose
50%
Dyslipidemia
50%
Drug Dose Titration
50%
Diseases
50%
Neuroscience
Diabetes Mellitus
100%
Adverse Effect
100%
Metformin
100%
Dyslipidemia
100%
Hyperglycemia
100%
Hypertension
100%
Pharmacology, Toxicology and Pharmaceutical Science
Tablet
100%
Diabetes Mellitus
50%
Hyperglycemia
50%
Non Insulin Dependent Diabetes Mellitus
50%
Monotherapy
50%
Metformin
50%
Side Effect
50%
Dyslipidemia
50%
Diseases
50%